X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OBI-992 is a novel antibody drug conjugate (ADC) cancer therapy targeting TROP2. It is being evaluated for the treatment of non-small cell lung cancer, small cell lung cancer & gastric cancer.
Lead Product(s): OBI-992
Therapeutic Area: Oncology Product Name: OBI-992
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biosion
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
OBI-992 is a TROP2-targeted antibody-drug conjugate that carries a potent topoisomerase I inhibitor payload to kill tumor cells. It is being evaluated for the treatment of advanced solid tumors, including non-small cell lung cancer, small cell lung cancer & gastric cancer.
Lead Product(s): OBI-992
Therapeutic Area: Oncology Product Name: OBI-992
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
A first in class monoclonal antibody cancer immunotherapy, OBI-888 targets Globo H, antibody, a glycolipid antigen expressed in up to 15 epithelial cancers.
Lead Product(s): OBI-888
Therapeutic Area: Oncology Product Name: OBI-888
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
OBI-999, uses Globo H antibody to recognize the cancer cells with high Globo H expression and releases the active drug to prevent tumor growth and kill tumor cells.
Lead Product(s): OBI-999
Therapeutic Area: Oncology Product Name: OBI-999
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
OBI-3424 can induce immunogenic cell death and demonstrated impressive synergistic efficacy in combination with Pembrolizumab in various cancer models, Emerging science also demonstrated poor survival in gastric cancer patients who have high Globo H and PD-L1 expression.
Lead Product(s): OBI-3424,Pembrolizumab
Therapeutic Area: Oncology Product Name: OBI-3424
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
The license agreement enables OBI Pharma to conduct further preclinical and clinical development, registration, and commercialization of BSI04702 as an Antibody Drug Conjugate and other derivative products.
Lead Product(s): BSI04702
Therapeutic Area: Oncology Product Name: BSI04702
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Biosion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 13, 2021
Details:
In the trial, OBI-833 showed a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. The company’s novel first-in-class immuno-oncology portfolio against Globo H includes: Adagloxad Simolenin and OBI-833, a Globo H active immunotherapy vaccine.
Lead Product(s): OBI-833
Therapeutic Area: Oncology Product Name: OBI-833
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 antigens in different tumor types.
Lead Product(s): OBI-3424,OBI-821
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
Second Orphan Drug Designation for OBI-999, Antibody-Drug Conjugate in combination with a validated payload (MMAE) & the antibody targeting Globo H, a glycolipid antigen found on multiple tumor types.
Lead Product(s): OBI-999
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
